Denali Therapeutics Reports Third-Quarter 2026 Results
Denali Therapeutics reported third-quarter 2026 financial results and business highlights; no figures or details were provided.
Related stories
ANGI Announces Global Workforce Reduction of 300 Roles
ANGI announced a global workforce reduction of 300 roles in an SEC filing.
M impact | EQUITY | Nov 03, 2026, 09:42 PM UTC
BioMarin Reports Third-Quarter Revenue of $1.02 Billion
Revenue rose 32% from $776.1 million a year earlier. Net loss widened to $122.8 million from $30.7 million, and diluted loss per share increased to $0.63 from $0.16.
M impact | EQUITY | Nov 03, 2026, 09:42 PM UTC
Glacier Bancorp Reports Third-Quarter 2026 Revenue of $329.8 Million
Revenue rose 26.5% year over year to $329.8 million, net income increased 54% to $104.6 million, and diluted EPS climbed to $0.80 from $0.57, supported by higher net interest incom
M impact | EQUITY | Nov 03, 2026, 09:42 PM UTC
Pulmonx Reports Third-Quarter 2026 Revenue of $22.84M
Revenue rose 6.2% year over year. Net loss narrowed to $8.39 million, and diluted loss per share improved to $0.19 from $0.34.
M impact | EQUITY | Nov 03, 2026, 09:42 PM UTC
Alaris Reports 2026 Third-Quarter Financial Results
Alaris reported record run-rate revenue of $231 million and 46% growth in net distributable cash flow.
M impact | EQUITY | Nov 03, 2026, 09:42 PM UTC
Revolve Group Reports Third-Quarter Revenue of $356 Million
Revenue rose 20.4% year over year to $356 million. Net income attributable to Revolve stockholders fell 31.7% to $14.5 million, while diluted EPS declined to $0.20 from $0.29.
M impact | EQUITY | Nov 03, 2026, 09:41 PM UTC